SCHEMBL4410176

SCHEMBL4410176

[CH2]c1ccc(OC(C)=O)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.62
JUN P05412 1/20 0.59
NFKB1 P19838 1/20 0.59
PTGS1 P23219 1/20 0.58
NR3C1 P04150 1/20 0.57
TNFSF11 O14788 1/20 0.55
VCP P55072 1/20 0.50
PKM P14618 2/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ALDH1A1 P00352 3/20 0.49
GAA P10253 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
BACE1 P56817 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11401919 0.93 TNFSF11 (0.55) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL9360952 0.90 TSHR (0.58) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL10425842 0.81 TSHR (0.66) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL27090 0.80 CA2 (0.54) TSHRNR3C1ALDH1A1GAAKDM4E
SCHEMBL2729632 0.79 TSHR (0.64) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL3328971 0.79 TSHR (0.64) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL18052474 0.79 TSHR (0.64) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL171836 0.79 TSHR (0.64) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL11347760 0.79 TSHR (0.64) TSHRJUNNFKB1PTGS1NR3C1
SCHEMBL28742168 0.79 ACHE (0.46) TSHRPTGS1NR3C1TNFSF11RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014144073-A2 AUGMENTING MOIETIES FOR ANTI-INFLAMMATORY COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-09-18 WO claimed
CN-1280578-A Bis-quaternary ammonium derivatives as neuromuscular relaxants NEWLAKSONT CO LTD (US) 2001-01-17 CN claimed
US-5990124-A ALKOXY AND/OR ACYLOXY DI- AND POLY-SUBSTITUTED ARALKYL AND ARALKENYL BIS-QUATERNARY AMMONIUM DERIVATIVES OF CYCLIC ALKANOL DIESTERS; SUCH AS BIS(N-(4-ACETOXY-3-METHOXYBENZYL) TROPANIUM-3-YL)-3,6-ENDOMETHYLENE-1,2,3,6-TETRAHYDROPHTHALATE GYERMEK LASZLO (US) 1999-11-23 US claimed
US-4200575-A 7[(2-Thiazolyl)-2-(oxoimino)acetamido]cephalosporin derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1980-04-29 US claimed
US-20090203774-A1 SUBSTITUTED BENZYL ESTER DERIVATIVE AND USE THEREOF AJINOMOTO CO., INC. (JP) 2009-08-13 US disclosed
CN-101125864-A Heteroaromatic inhibitor for fructose-1,6-bisphosphatase METABASIS THERAPEUTICS INC (US) 2008-02-20 CN disclosed
CN-100349904-C Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase METABASIS THERAPEUTICS INC (US) 2007-11-21 CN disclosed
CN-1900087-A Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase METABASIS THERAPEUTICS INC (US) 2007-01-24 CN disclosed
CN-1704423-A Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase METABASIS THERAPEUTICS INC (US) 2005-12-07 CN disclosed
CN-1215076-C Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase METABASIS THERAPEUTICS INC (US) 2005-08-17 CN disclosed
US-20040110665-A1 Desleucyl glycopeptide antibiotics and methods of making same KAHNE DANIEL (US) 2004-06-10 US disclosed
US-6699836-B2 Vancomycin analogs THE TRUSTEES OF PRINCETON UNIVERSITY 2004-03-02 US disclosed
US-4812446-A CAPSAICINOID AND SALICYLATE THE PROCTER & GAMBLE COMPANY (US) 1989-03-14 US disclosed
EP-0306060-A2 Pharmaceutical products providing enhanced analgesia THE PROCTER & GAMBLE COMPANY (US) 1989-03-08 EP disclosed
US-4681897-A CAPSAICIN OR ANALOGUE WITH A NONSTEROIDAL ANALGESIC THE PROCTER & GAMBLE COMPANY (US) 1987-07-21 US disclosed
US-4599342-A MIXTURE OF CAPSAICIN WITH OPIOID THE PROCTER & GAMBLE COMPANY (US) 1986-07-08 US disclosed
EP-0149545-A2 Pharmaceutical products providing enhanced analgesia THE PROCTER & GAMBLE COMPANY (US) 1985-07-24 EP disclosed
EP-0149544-A2 Pharmaceutical products providing enhanced analgesia THE PROCTER & GAMBLE COMPANY (US) 1985-07-24 EP disclosed
US-4280008-A CHEMICAL INTERMEDIATES FOR OPTICALLY ACTIVE AMINO ACIDS BASF AKTIENGESELLSCHAFT (DE) 1981-07-21 US disclosed
US-4200575-A 7[(2-Thiazolyl)-2-(oxoimino)acetamido]cephalosporin derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1980-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110665-A1 Desleucyl glycopeptide antibiotics and methods of making same FUT6, FUT5, ST6GAL1 TSHR 2445/4885JUN 2419/4885NFKB1 2492/4885
US-20090203774-A1 SUBSTITUTED BENZYL ESTER DERIVATIVE AND USE THEREOF MEP1B, EBP, MEP1A TSHR 3982/4885JUN 3580/4885NFKB1 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.